MPRIP

Across TCGA pan-cancer cohorts, MPRIP mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MPRIP data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher MPRIP mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MPRIP expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

GBM, LUAD, and HNSC are the cancer types where MPRIP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.248	0.545	.016	2	view →
LUAD	DFS	Quartile	II,III,IV	0.749	0.981	.042	2	view →
HNSC	DFS	Tertile	All	0.979	0.909	.038	2	view →
CCRCC	DFS	Median	III,IV	0.753	0.467	.036	2	view →
LSCC	DFS	Quartile	III,IV	0.299	0.789	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MPRIP–GBM (OS)

Open the GBM breakdown →